<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113154</article-id><article-id pub-id-type="publisher-id">ACM-40954</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_85409966.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  维持性血液透析患者的COX生存分析
  Survival Analysis of Maintenance Hemodialysis Patients
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>媛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>单</surname><given-names>文红</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>黄</surname><given-names>俊彦</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>安</surname><given-names>茜</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>颖川</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>解</surname><given-names>秀荣</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>季</surname><given-names>文萱</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff3"><addr-line>青岛大学第二临床医学院肾内科，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1074</fpage><lpage>1082</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨影响维持性血液透析(maintenance hemodialysis, MHD)患者远期生存的因素，以期提高MHD患者的生存率和生存质量。方法：回顾性分析2010年~2020年青岛市中心医院血液净化中心确诊为终末期肾病(end stage renal disease, ESRD)并行血液透析治疗超过3个月的296名患者的生存情况，并就透析前病历资料对生存率的影响进行了分析。采用回顾性病例对照分析方法，根据终点事件将患者分为存活组和死亡组收集两组患者开始接受MHD时的各项临床及生化指标；采用单因素、多因素COX回归分析MHD远期死亡的主要原因及相关危险因素。结果：296例患者1年、3年、5年、10年的累积生存率分别为：90.9%，80.1%，80.0%，63.8%，COX回归分析结果显示：开始透析年龄 ≥ 60岁(HR = 2.415, P &lt; 0.05)、合并糖尿病(HR = 2.209, P &lt; 0.05)、高血钾(HR = 2.757, P &lt; 0.05)、高尿酸血症(HR = 1.980, P &lt; 0.05)、贫血(HR = 2.490, P &lt; 0.05)、高C反应蛋白水平(HR = 1.005, P &lt; 0.05)为影响MHD患者生存时间的独立危险因素。结论：开始透析年龄较大、合并糖尿病、高血钾、高尿酸血症、贫血、炎症状态的患者死亡率高。积极治疗基础病、加强合并症防治、纠正透析前高血糖、高血钾和高尿酸水平，改善贫血和炎症状态能提高尿毒症MHD患者的长期生存率，延长生存时间。
    Objective: To explore the factors affecting the long-term survival of maintenance hemodialysis (maintenance hemodialysis, MHD) patients in order to improve the survival rate and quality of life of MHD patients. Methods: The survival conditions of 296 patients diagnosed with end-stage renal disease (end stage renal disease, ESRD) and hemodialysis for more than 3 months in the Blood purification Center of Qingdao Central Hospital from 2010 to 2020 were analyzed retrospectively, and the effect of pre-dialysis medical records on survival rate was analyzed. The patients were divided into the survival group and the death group according to the end events by retrospective case-control analysis, the clinical and biochemical indexes of the two groups at the beginning of MHD were collected, and the main causes and related risk factors of long-term death of MHD were analyzed by univariate and multivariate COX regression. Results: The cumulative survival rate of 296 patients at 1 year, 3 years, 5 years and 10 years was 90.9%, 80.1%, 80.0% and 63.8%, respectively. The results of COX regression analysis showed that the age of starting dialysis ≥ 60 years old (HR = 2.415, P &lt; 0.05), diabetes mellitus (HR = 2.209, P &lt; 0.05), hyperkalemia (HR = 2.757, P &lt; 0.05), hyperuricemia (HR = 1.980, P &lt; 0.05), anemia (HR = 2.490, P &lt; 0.05 and high C-reactive protein level (HR = 1.005, P &lt; 0.05) were independent risk factors affecting the survival time of MHD patients. Conclusion: The patients with older age at the beginning of dialysis, complicated with diabetes, hyperkalemia, hyperuricemia, anemia and inflammatory state have higher mortality. Active treatment of underlying diseases, strengthening the prevention and treatment of complications, correcting the levels of hyperglycemia, hyperkalemia and uric acid before dialysis, and improving anemia and inflammation can improve the long-term survival rate and prolong the survival time of uremic MHD patients. 
  
 
</p></abstract><kwd-group><kwd>尿毒症，维持性血液透析，生存分析，影响因素, Uremia</kwd><kwd> Maintenance Hemodialysis</kwd><kwd> Survival Analysis</kwd><kwd> Influencing Factors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨影响维持性血液透析(maintenance hemodialysis, MHD)患者远期生存的因素，以期提高MHD患者的生存率和生存质量。方法：回顾性分析2010年~2020年青岛市中心医院血液净化中心确诊为终末期肾病(end stage renal disease, ESRD)并行血液透析治疗超过3个月的296名患者的生存情况，并就透析前病历资料对生存率的影响进行了分析。采用回顾性病例对照分析方法，根据终点事件将患者分为存活组和死亡组收集两组患者开始接受MHD时的各项临床及生化指标；采用单因素、多因素COX回归分析MHD远期死亡的主要原因及相关危险因素。结果：296例患者1年、3年、5年、10年的累积生存率分别为：90.9%，80.1%，80.0%，63.8%，COX回归分析结果显示：开始透析年龄 ≥ 60岁(HR = 2.415, P &lt; 0.05)、合并糖尿病(HR = 2.209, P &lt; 0.05)、高血钾(HR = 2.757, P &lt; 0.05)、高尿酸血症(HR = 1.980, P &lt; 0.05)、贫血(HR = 2.490, P &lt; 0.05)、高C反应蛋白水平(HR = 1.005, P &lt; 0.05)为影响MHD患者生存时间的独立危险因素。结论：开始透析年龄较大、合并糖尿病、高血钾、高尿酸血症、贫血、炎症状态的患者死亡率高。积极治疗基础病、加强合并症防治、纠正透析前高血糖、高血钾和高尿酸水平，改善贫血和炎症状态能提高尿毒症MHD患者的长期生存率，延长生存时间。</p></sec><sec id="s2"><title>关键词</title><p>尿毒症，维持性血液透析，生存分析，影响因素</p></sec><sec id="s3"><title>Survival Analysis of Maintenance Hemodialysis Patients<sup> </sup></title><p>Yuan Liu<sup>1</sup>, Wenhong Shan<sup>2</sup>, Junyan Huang<sup>2</sup>, Qian An<sup>2</sup>, Yingchuan Xu<sup>2</sup>, Xiurong Xie<sup>1</sup>, Wenxuan Ji<sup>2*</sup></p><p><sup>1</sup>Department of Medicine, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Nephrology, The Second Clinical Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/37-1572029x5_hanspub.png" /></p><p>Received: Feb. 11<sup>th</sup>, 2021; accepted: Mar. 1<sup>st</sup>, 2021; published: Mar. 16<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/37-1572029x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the factors affecting the long-term survival of maintenance hemodialysis (maintenance hemodialysis, MHD) patients in order to improve the survival rate and quality of life of MHD patients. Methods: The survival conditions of 296 patients diagnosed with end-stage renal disease (end stage renal disease, ESRD) and hemodialysis for more than 3 months in the Blood purification Center of Qingdao Central Hospital from 2010 to 2020 were analyzed retrospectively, and the effect of pre-dialysis medical records on survival rate was analyzed. The patients were divided into the survival group and the death group according to the end events by retrospective case-control analysis, the clinical and biochemical indexes of the two groups at the beginning of MHD were collected, and the main causes and related risk factors of long-term death of MHD were analyzed by univariate and multivariate COX regression. Results: The cumulative survival rate of 296 patients at 1 year, 3 years, 5 years and 10 years was 90.9%, 80.1%, 80.0% and 63.8%, respectively. The results of COX regression analysis showed that the age of starting dialysis ≥ 60 years old (HR = 2.415, P &lt; 0.05), diabetes mellitus (HR = 2.209, P &lt; 0.05), hyperkalemia (HR = 2.757, P &lt; 0.05), hyperuricemia (HR = 1.980, P &lt; 0.05), anemia (HR = 2.490, P &lt; 0.05 and high C-reactive protein level (HR = 1.005, P &lt; 0.05) were independent risk factors affecting the survival time of MHD patients. Conclusion: The patients with older age at the beginning of dialysis, complicated with diabetes, hyperkalemia, hyperuricemia, anemia and inflammatory state have higher mortality. Active treatment of underlying diseases, strengthening the prevention and treatment of complications, correcting the levels of hyperglycemia, hyperkalemia and uric acid before dialysis, and improving anemia and inflammation can improve the long-term survival rate and prolong the survival time of uremic MHD patients.</p><p>Keywords:Uremia, Maintenance Hemodialysis, Survival Analysis, Influencing Factors</p><disp-formula id="hanspub.40954-formula22"><graphic xlink:href="//html.hanspub.org/file/37-1572029x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/37-1572029x8_hanspub.png" /> <img src="//html.hanspub.org/file/37-1572029x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>尿毒症的发病率逐年增高 [<xref ref-type="bibr" rid="hanspub.40954-ref1">1</xref>]，MHD是尿毒症患者最主要的治疗方式。有研究指出 [<xref ref-type="bibr" rid="hanspub.40954-ref2">2</xref>]，大约26%的血液透析患者在1年内死亡，因而如何降低患者的长期死亡率为临床研究的重点。本研究对我院透析中心近10年的尿毒症MHD患者生存状况的影响因素进行了探究，以期能为今后的临床防治提供参考。</p></sec><sec id="s6"><title>2. 对象和方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>2010年10月1日至 2020年10月31日在青岛市中心医院血液净化中心行规律性血液透析的ESRD患者，根据CKD-EPI公式估算的肾小球滤过率(eGFR) [<xref ref-type="bibr" rid="hanspub.40954-ref3">3</xref>] 进入透析时研究对象均处于CKD 4期或5期。 [CKD-EPI公式eGFR = a &#215; (血清肌酐/b)<sup>c</sup> &#215; (0.993)<sup>年龄</sup>。(其中，女性a：144；b：0.7；血清肌酐 ≤ 0.7 mg/dl时c = −0.329，血清肌酐 &gt; 0.7 mg/dl时，c = −1.209；男性：a：141；b：0.9；血清肌酐 ≤ 0.7 mg/dl时c = −0.411，血清肌酐 &gt; 0.7 mg/dl时，c = −1.209)]</p><p>纳入标准：① MHD治疗 ≥ 3月，年龄 ≥ 18岁，性别不限；② 随访至2020年10月31日，转归明确的患者。</p><p>排除标准：① 基本信息资料缺失，如性别、年龄、首次透析时间等；② 透析时间 ≤ 3个月；③ 年龄 &lt; 18岁；④ 无实验室数据或数据缺失严重；⑤ 急性肾损伤需临时血液透析者。</p><p>本研究符合医学伦理学标准，得到医院伦理委员会批准，所有治疗取得患者或家属的知情同意。</p></sec><sec id="s6_2"><title>2.2. 研究因素</title><p>利用医院的电子病历系统查询患者资料，建立信息数据库。采用回顾性方法收集患者的社会人口学信息(姓名、性别、年龄、身高、体重等)，MHD情况(血管通路、透析开始时间)，基础疾病(糖尿病、高血压、心血管疾病)，进入透析前多项实验室指标(血常规、肝功能、肾功能、电解质、血脂等)，比较不同因素对患者生存时间的影响。</p></sec><sec id="s6_3"><title>2.3. 随访终点</title><p>随访至终点事件发生或2020年10月31日，以患者生存率作为预后评价指标。随访期间转腹膜透析和(或)肾移植的患者，状态算为存活。患者生存终点事件为全因死亡。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>采用《SPSS 25.0》统计软件包进行数据处理与分析，计量资料采用均数 &#177; 标准差( x &#175; &#177; s)或中位数M (四分位间距)表示，两组间比较采用独立样本t检验或Mann-Whitney U检验。计数资料采用频数(百分比) 表示组间比较采用卡方检验。采用COX比例风险模型筛选影响预后的危险因素，其中性别以男性为参照，开始透析时年龄以&lt;60岁组为参照，MHD的原发病因以原发性肾小球疾病为参照。为了避免漏掉重要因素，将单因素分析中显著性检验水准α放宽至0.2，并将某些可能的影响因素纳入多因素分析。根据COX回归结果，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 两组患者的一般情况</title><p>纳入296例患者，男性193例(65%)，女性103例(35%)，开始透析年龄20~86岁，平均年龄58 &#177; 13岁，中位年龄59 (50~67)岁，将研究对象按照生存状况分为生存组185例(62.5%)和死亡组111例(37.5%)。1 年，3年，5年和10年累积生存率分别为90.9%，80.1%，80.0%，63.8%。死亡组从首次MHD开始到死亡的平均时间(43.8 &#177; 36.1)个月。原发病分别为慢性肾小球肾炎21例(18.9%)，糖尿病肾病59例(53.2%)，高血压性肾损害18例(16.2%)，多囊肾4例(3.6%)，梗阻性肾病4例(3.6%)，狼疮性肾炎4例(3.6%)，ANCA 相关性血管炎肾损伤1例(0.9%)。存活组原发病分别为慢性肾小球肾炎69例(37.3%)，糖尿病肾病77例(41.6%)，高血压性肾损害15例(8.1%)，多囊肾13例(7.0%)，ANCA相关性血管炎肾损伤3例(1.6%)，梗阻性肾病2例(1.1%)，狼疮性肾炎2例(1.1%)，多发性骨髓瘤性肾损害2例(1.1%)，紫癜性肾炎1例(0.5%)，痛风性肾病1例(0.5%)，两组间原发病差异有统计学意义(P &lt; 0.05)。</p></sec><sec id="s7_2"><title>3.2. 两组患者的基本情况</title><p>两组患者的开始透析年龄、BMI、原发病、血管通路、高血压、糖尿病、高血钾、高尿酸血症、低蛋白血症、贫血、感染、低血压患病情况差异具有统计学意义(P &lt; 0.05)。见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of basic conditions between survival group and death grou</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >总体(296)</th><th align="center" valign="middle" >死亡组(111)</th><th align="center" valign="middle" >生存组(185)</th><th align="center" valign="middle" >x<sup>2</sup>/t/z</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >性别，n(%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.010</td><td align="center" valign="middle" >0.156</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >193 (66.4)</td><td align="center" valign="middle" >78 (71.4)</td><td align="center" valign="middle" >115 (64.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >103 (33.6)</td><td align="center" valign="middle" >33 (28.6)</td><td align="center" valign="middle" >70 (35.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >开始透析的年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >8.309</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >&lt;60岁</td><td align="center" valign="middle" >152 (51.6)</td><td align="center" valign="middle" >45 (36.5)</td><td align="center" valign="middle" >107 (57.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥60岁</td><td align="center" valign="middle" >144 (48.4)</td><td align="center" valign="middle" >66 (63.5)</td><td align="center" valign="middle" >78 (42.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >体质量指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7.835</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >&lt;24 kg/m<sup>2</sup>, n (%)</td><td align="center" valign="middle" >159 (57.6)</td><td align="center" valign="middle" >48 (57.1)</td><td align="center" valign="middle" >111 (57.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥24 kg/m<sup>2</sup>, n (%)</td><td align="center" valign="middle" >137 (42.4)</td><td align="center" valign="middle" >63 (42.9)</td><td align="center" valign="middle" >74 (42.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >透析龄(月)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >透析龄(月)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.052</td><td align="center" valign="middle" >0.305</td></tr><tr><td align="center" valign="middle" >&lt;60月，n (%)</td><td align="center" valign="middle" >200 (68.7)</td><td align="center" valign="middle" >79 (68.3)</td><td align="center" valign="middle" >121 (68.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥60月，n (%)</td><td align="center" valign="middle" >96 (31.3)</td><td align="center" valign="middle" >32 (31.7)</td><td align="center" valign="middle" >64 (31.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >原发病，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >13.894</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >糖尿病肾病</td><td align="center" valign="middle" >136 (45.2)</td><td align="center" valign="middle" >59 (55.6)</td><td align="center" valign="middle" >77 (40.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >慢性肾小球疾病</td><td align="center" valign="middle" >70 (32.3)</td><td align="center" valign="middle" >21 (20.6)</td><td align="center" valign="middle" >69 (37.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高血压肾损害</td><td align="center" valign="middle" >33 (10.1)</td><td align="center" valign="middle" >18 (12.7)</td><td align="center" valign="middle" >15 (9.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >37 (12.4)</td><td align="center" valign="middle" >13 (11.1)</td><td align="center" valign="middle" >24 (13.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血管通路</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14.417</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >动静脉内瘘，n (%)</td><td align="center" valign="middle" >243 (85.3)</td><td align="center" valign="middle" >79 (69.8)</td><td align="center" valign="middle" >164 (91.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中心静脉置管，n (%)</td><td align="center" valign="middle" >53 (14.7)</td><td align="center" valign="middle" >32 (30.2)</td><td align="center" valign="middle" >21 (8.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.724</td></tr><tr><td align="center" valign="middle" >心血管疾病，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.125</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >226 (79.3)</td><td align="center" valign="middle" >86 (87.3)</td><td align="center" valign="middle" >140 (76.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >70 (20.7)</td><td align="center" valign="middle" >25 (12.7)</td><td align="center" valign="middle" >45 (24.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.017</td></tr><tr><td align="center" valign="middle" >高血压，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5.701</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >260 (87.1)</td><td align="center" valign="middle" >91 (74.6)</td><td align="center" valign="middle" >169 (92.2)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >36 (12.9)</td><td align="center" valign="middle" >20 (25.4)</td><td align="center" valign="middle" >16 (7.8)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >糖尿病，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >23.492</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >168 (52.1)</td><td align="center" valign="middle" >83 (68.3)</td><td align="center" valign="middle" >85 (45.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >128 (47.9)</td><td align="center" valign="middle" >28 (31.7)</td><td align="center" valign="middle" >100 (54.5)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >高血钾，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >14.049</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >85 (52.5)</td><td align="center" valign="middle" >46 (52.4)</td><td align="center" valign="middle" >39 (52.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >211 (47.5)</td><td align="center" valign="middle" >65 (47.6)</td><td align="center" valign="middle" >146 (47.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >高尿酸血症，n (%)</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" >15.177</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >61 (22.1)</td><td align="center" valign="middle" >36 (41.3)</td><td align="center" valign="middle" >25 (14.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >235 (77.9)</td><td align="center" valign="middle" >75 (58.7)</td><td align="center" valign="middle" >160 (85.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >低白蛋白血症，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >27.315</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >60 (20.3)</td><td align="center" valign="middle" >40 (44.4)</td><td align="center" valign="middle" >20 (10.4)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >236 (79.7)</td><td align="center" valign="middle" >71 (55.6)</td><td align="center" valign="middle" >165 (89.6)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >贫血，n (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >48.942</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >72 (25.3)</td><td align="center" valign="middle" >52 (65.1)</td><td align="center" valign="middle" >20 (9.1)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >224 (74.7)</td><td align="center" valign="middle" >59 (34.9)</td><td align="center" valign="middle" >165 (90.9)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >感染，n (%))</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9.520</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >197 (67.3)</td><td align="center" valign="middle" >86 (77.8)</td><td align="center" valign="middle" >111 (63.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >99 (32.7)</td><td align="center" valign="middle" >25 (22.2)</td><td align="center" valign="middle" >74 (37.0)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >低血压</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >21.083</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >是</td><td align="center" valign="middle" >36 (10.6)</td><td align="center" valign="middle" >26 (27.0%)</td><td align="center" valign="middle" >10 (3.9%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >否</td><td align="center" valign="middle" >260 (89.4)</td><td align="center" valign="middle" >85 (73.0%)</td><td align="center" valign="middle" >175 (96.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.039</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. 生存组和死亡组基本情况比较</p><p>实验室检查：比较生存组和死亡组患者透析前的多项实验室检查，结果显示，死亡组白细胞、谷草氨酸转氨酶、甘油三酯、血糖、校正钙、C反应蛋白水平明显高于存活组(P &lt; 0.05)，而血红蛋白、血小板、血清白蛋白、血尿酸、尿素氮、总胆固醇、高密度脂蛋白、低密度脂蛋白、血钠水平明显低于存活组(P &lt; 0.05)。见表2。</p></sec><sec id="s7_3"><title>3.3. 死亡组患者长期死亡原因分析</title><p>在111例患者死亡原因中，心血管疾病39例(35.1%)，多脏器衰竭18例(16.2%)，脑出血16例(14.4%)，感染12例(10.8%)，肿瘤14例(12.6%)，高钾血症5例(4.5%)，消化道出血2例(1.8%)，休克2例(1.8%)，尿毒症脑病1例(0.9%)，肝性脑病1例(0.9%)，乳酸酸中毒1例(0.9%)。见表2。</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of survival group and death laborator</title></caption><table-wrap id="2_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" >总体(296)</th><th align="center" valign="middle" >死亡组(111)</th><th align="center" valign="middle" >生存组(185)</th><th align="center" valign="middle" >t/U</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >WBC (&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >6.84 (4.97, 9.11)</td><td align="center" valign="middle" >8.64 (5.26, 11.14)</td><td align="center" valign="middle" >6.24 (4.70, 7.69)</td><td align="center" valign="middle" >−4.042</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >Hb (g/L)</td><td align="center" valign="middle" >97 (79, 115)</td><td align="center" valign="middle" >98 (78, 116)</td><td align="center" valign="middle" >97 (80, 112)</td><td align="center" valign="middle" >−0.491</td><td align="center" valign="middle" >0.623</td></tr><tr><td align="center" valign="middle" >Plt (&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >165 (116, 219)</td><td align="center" valign="middle" >135 (96, 196)</td><td align="center" valign="middle" >171 (129, 224)</td><td align="center" valign="middle" >−3.008</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Alb (g/L)</td><td align="center" valign="middle" >34.9 (29.5, 39.1)</td><td align="center" valign="middle" >31.8 (26.8, 36.6)</td><td align="center" valign="middle" >36.3 (31.6, 40.0)</td><td align="center" valign="middle" >−4.627</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >FBG (&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >6.6 (5.2, 8.1)</td><td align="center" valign="middle" >7.4 (6.2, 9.2)</td><td align="center" valign="middle" >6.0 (4.8, 7.4)</td><td align="center" valign="middle" >−5.35</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >UA (μmol/L)</td><td align="center" valign="middle" >456.8 (355, 537.0)</td><td align="center" valign="middle" >432 (329, 519)</td><td align="center" valign="middle" >480.0 (360, 542.5)</td><td align="center" valign="middle" >−4.627</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >BUN (mmol/L)</td><td align="center" valign="middle" >31.35 (24.30, 37.98)</td><td align="center" valign="middle" >29.5 (22.5, 38.0)</td><td align="center" valign="middle" >32.7 (25.55, 38.00)</td><td align="center" valign="middle" >−1.765</td><td align="center" valign="middle" >0.078</td></tr><tr><td align="center" valign="middle" >ALT (u/L)</td><td align="center" valign="middle" >12 (8, 18)</td><td align="center" valign="middle" >12 (6, 19)</td><td align="center" valign="middle" >12 (9, 18)</td><td align="center" valign="middle" >−0.871</td><td align="center" valign="middle" >0.384</td></tr><tr><td align="center" valign="middle" >AST (u/L)</td><td align="center" valign="middle" >15 (11, 20)</td><td align="center" valign="middle" >16 (11, 41)</td><td align="center" valign="middle" >15 (11, 19)</td><td align="center" valign="middle" >−2.409</td><td align="center" valign="middle" >0.016</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><table><tbody><thead><tr><th align="center" valign="middle" >TC (mmol/L)</th><th align="center" valign="middle" >4.33 (3.46, 5.45)</th><th align="center" valign="middle" >4.08 (2.88, 4.97)</th><th align="center" valign="middle" >4.58 (3.72, 5.60)</th><th align="center" valign="middle" >−3.395</th><th align="center" valign="middle" >0.001</th></tr></thead><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >1.54 (1.05, 2.11)</td><td align="center" valign="middle" >1.80 (1.32, 2.21)</td><td align="center" valign="middle" >1.39 (0.94, 2.08)</td><td align="center" valign="middle" >−3.31</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >HDL-C (mmol/L)</td><td align="center" valign="middle" >1.23 (1.04, 1.52)</td><td align="center" valign="middle" >1.12 (0.94, 1.32)</td><td align="center" valign="middle" >1.32 (1.14, 1.60)</td><td align="center" valign="middle" >−4.95</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >LDL-C (mmol/L)</td><td align="center" valign="middle" >2.73 (2.02, 3.62)</td><td align="center" valign="middle" >2.45 (1.63, 3.52)</td><td align="center" valign="middle" >2.86 (2.32, 3.84)</td><td align="center" valign="middle" >−3.162</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >钙(mmol/L)</td><td align="center" valign="middle" >2.0 (1.91, 2.2)</td><td align="center" valign="middle" >2.1 (1.9, 2.3)</td><td align="center" valign="middle" >2.0 (1.9, 2.2)</td><td align="center" valign="middle" >−1.802</td><td align="center" valign="middle" >0.072</td></tr><tr><td align="center" valign="middle" >校正钙(mmol/L)</td><td align="center" valign="middle" >2.19 (1.99, 2.35)</td><td align="center" valign="middle" >2.25 (2.05, 2.41)</td><td align="center" valign="middle" >2.14 (1.94, 2.30)</td><td align="center" valign="middle" >−3.051</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >磷(mmol/L)</td><td align="center" valign="middle" >1.91 (1.51, 2.24)</td><td align="center" valign="middle" >1.83 (1.31, 2.21)</td><td align="center" valign="middle" >1.92 (1.59, 2.25)</td><td align="center" valign="middle" >−1.778</td><td align="center" valign="middle" >0.075</td></tr><tr><td align="center" valign="middle" >钾(mmol/L)</td><td align="center" valign="middle" >4.8 (4.2, 5.6)</td><td align="center" valign="middle" >5.0 (4.0, 6.0)</td><td align="center" valign="middle" >4.8 (4.2, 5.4)</td><td align="center" valign="middle" >−1.351</td><td align="center" valign="middle" >0.177</td></tr><tr><td align="center" valign="middle" >钠(mmol/L)</td><td align="center" valign="middle" >138 (135, 142)</td><td align="center" valign="middle" >136 (133, 140)</td><td align="center" valign="middle" >139 (136, 142)</td><td align="center" valign="middle" >−3.394</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >CRP (&#215;10<sup>9</sup>/L)</td><td align="center" valign="middle" >6.31 (0.98, 31.73)</td><td align="center" valign="middle" >24 (10, 92.15)</td><td align="center" valign="middle" >2.3 (0.5, 8.56)</td><td align="center" valign="middle" >−9.342</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 生存组和死亡组实验室资料比较</p><p>WBC：白细胞计数；Hb：血红蛋白；PLT：血小板计数；Alb：血清白蛋白；UA：尿酸；BUN：尿素氮；ALT：谷丙氨酸转移酶；AST：谷草氨酸转移酶；TC：总胆固醇；TG：甘油三酯；HDL-C：高密度脂蛋白；LDL-C：低密度脂蛋白；校正钙 = 钙(mmol/L) + 0.02 [40 – Alb (g/L)] mmol/L。</p></sec><sec id="s7_4"><title>3.4. 总体生存率</title><p>随着血液透析时间延长，患者的生存率逐渐下降，1年生存率为90.9%，3年生存率80.1%，5年生存率80.0%，10 年生存率63.8%，生存期最长1例超过166月(13年)仍在规律血液透析治疗。</p></sec><sec id="s7_5"><title>3.5. 多因素生存分析</title><p>单因素COX回归分析结果显示，开始透析年龄 ≥ 60岁、原发病为糖尿病肾病、高血压肾损害、体质量指数 ≥ 24 kg/m<sup>2</sup>、合并糖尿病、高血钾、高尿酸血症、低白蛋白血症、贫血、低血压、高白细胞计数、血糖、C反应蛋白水平与患者长期死亡呈正相关(P &lt; 0. 05)，患者性别为女性、自体内瘘作为血管通路、合并高血压，高密度脂蛋白与患者长期死亡呈负相关(P &lt; 0. 05)。将单因素COX回归中P &lt; 0.2的因素，进行多因素COX回归分析。 结果显示，开始透析年龄 ≥ 60岁、合并糖尿病、高血钾、高尿酸血症、贫血、C反应蛋白是尿毒症MHD患者长期死亡的独立危险因素。见表3。</p><table-wrap-group id="3"><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> COX regression analysis of short-term death risk factors in uremic patients with MH</title></caption><table-wrap id="3_1"><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >变量</th><th align="center" valign="middle"  colspan="3"  >单因素分析</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="3"  >多因素分析</th></tr></thead><tr><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >HR</td><td align="center" valign="middle" >95%CI</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >0.635</td><td align="center" valign="middle" >0.41~0.958</td><td align="center" valign="middle" >0.030</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >开始透析年龄</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;60岁</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥60岁</td><td align="center" valign="middle" >2.956</td><td align="center" valign="middle" >2.000~4.368</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.267</td><td align="center" valign="middle" >1.519~3.384</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >原发病</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >慢性肾小球肾炎</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >糖尿病肾病</td><td align="center" valign="middle" >2.143</td><td align="center" valign="middle" >1.300~3.534</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><table-wrap id="3_2"><table><tbody><thead><tr><th align="center" valign="middle" >高血压肾损害</th><th align="center" valign="middle" >2.578</th><th align="center" valign="middle" >1.372~4.847</th><th align="center" valign="middle" >0.003</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >其他</td><td align="center" valign="middle" >1.656</td><td align="center" valign="middle" >0.828~3.309</td><td align="center" valign="middle" >0.154</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >体质量指数</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >&lt;24 kg/m<sup>2</sup></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥24 kg/m<sup>2</sup></td><td align="center" valign="middle" >1.671</td><td align="center" valign="middle" >1.147~2.435</td><td align="center" valign="middle" >0.007</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >通路</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >中心静脉导管</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >自体内瘘</td><td align="center" valign="middle" >0.377</td><td align="center" valign="middle" >0.250~0.570</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高血压</td><td align="center" valign="middle" >0.572</td><td align="center" valign="middle" >0.352~0.930</td><td align="center" valign="middle" >0.024</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >糖尿病</td><td align="center" valign="middle" >2.845</td><td align="center" valign="middle" >1.84~4.380</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.287</td><td align="center" valign="middle" >1.479~3.536</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >高血钾</td><td align="center" valign="middle" >2.095</td><td align="center" valign="middle" >1.430~3.072</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.766</td><td align="center" valign="middle" >1.810~4.227</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >高尿酸血症</td><td align="center" valign="middle" >2.946</td><td align="center" valign="middle" >1.967~4.412</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.084</td><td align="center" valign="middle" >1.360~3.193</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >低白蛋白</td><td align="center" valign="middle" >2.582</td><td align="center" valign="middle" >1.751~3.809</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >贫血</td><td align="center" valign="middle" >3.345</td><td align="center" valign="middle" >2.303~4.859</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.404</td><td align="center" valign="middle" >1.606~3.599</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >感染</td><td align="center" valign="middle" >1.42</td><td align="center" valign="middle" >0.909~2.218</td><td align="center" valign="middle" >0.124</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >低血压</td><td align="center" valign="middle" >2.234</td><td align="center" valign="middle" >1.438~3.470</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >白细胞计数</td><td align="center" valign="middle" >1.057</td><td align="center" valign="middle" >1.031~1.083</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >血糖</td><td align="center" valign="middle" >1.094</td><td align="center" valign="middle" >1.048~1.142</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >AST(u/L)</td><td align="center" valign="middle" >1.000</td><td align="center" valign="middle" >1.000~1.001</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >高密度脂蛋白</td><td align="center" valign="middle" >0.358</td><td align="center" valign="middle" >0.218~0.589</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >C反应蛋白</td><td align="center" valign="middle" >1.006</td><td align="center" valign="middle" >1.004~1.007</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.005</td><td align="center" valign="middle" >1.003~1.007</td><td align="center" valign="middle" >0.000</td></tr></tbody></table></table-wrap></table-wrap-group><p>表3. 尿毒症MHD患者长期死亡危险因素COX回归分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>MHD是目前ESRD患者的主要治疗手段，尽管近年来血液透析技术不断完善，患者的生存率及生存质量仍不理想。如何提高 MHD患者的生存质量，延长其生存期，降低病死率，成为了血液透析领域的重要课题。因此，了解影响血液透析患者生存率的因素，进行及时合理的临床干预有着非常重要的临床意义。</p><p>我院近10年MHD患者短期死亡率为37.5%。心脑血管事件、感染、肿瘤、高钾血症及消化道大出血等均是影响MHD 患者死亡的原因。其中死于心脑血管疾病的占37.95%，位于第1位，与国内外大部分研究结果类似 [<xref ref-type="bibr" rid="hanspub.40954-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref7">7</xref>]，因此加强对尿毒症血液透析患者的心脑血管疾病防治助于改善尿毒症MHD患者短期生存率。</p><p>年龄是独立危险因素。笔者所在中心血液透析患者以中老年人群为主，与全国、山西、武汉均为同样的趋势 [<xref ref-type="bibr" rid="hanspub.40954-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref6">6</xref>]。本研究显示随着首次透析年龄的升高，患者死亡的风险随之增加；既往也有诸多研究证实老年ESRD患者的死亡率较高 [<xref ref-type="bibr" rid="hanspub.40954-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref8">8</xref>] 考虑与老年人常并发高血压、糖尿病、冠状动脉粥样硬化性心脏病等多种疾病有关。</p><p>肾性贫血是CKD-MHD患者的常见并发症。肾性贫血的发病机制复杂，内源性EPO缺乏或相对缺乏是肾性贫血的主要原因。贫血的发生率和严重程度随着肾功能的下降而增加，90%以上的终末期肾病患者被诊断为贫血 [<xref ref-type="bibr" rid="hanspub.40954-ref9">9</xref>]。它不仅影响生活质量，还会肾性贫血导致血液透析患者疲劳、心悸和呼吸困难，影响生活质量，而且也是血液透析患者预后不良的重要标志 [<xref ref-type="bibr" rid="hanspub.40954-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref11">11</xref>]，增加心血管事件和全因死亡率。</p><p>在健康状态下，血钾通常维持在3.5~5.5 mmol/l之间。血钾是静息膜电位的关键决定因素，稳态是维持正常神经和心脏传导所必需的。高钾血症在肾功能衰竭患者中很常见，原因是肾钾排泄减少，在极端情况下会导致心律和心脏静息紊乱。透析前高血钾水平被认为是HD患者突然死亡和全因死亡的危险因素 [<xref ref-type="bibr" rid="hanspub.40954-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref13">13</xref>]。</p><p>C反应蛋白是炎症的标志物。尿毒症患者在血液透析过程中常发生与炎症相关的感染 [<xref ref-type="bibr" rid="hanspub.40954-ref14">14</xref>]。且尿毒症患者常合并肾性贫血并发心力衰竭，有研究证实，C反应蛋白水平与心力衰竭和左心室肥厚有关，可作为判断患者心脑血管疾病能力和风险的指标 [<xref ref-type="bibr" rid="hanspub.40954-ref15">15</xref>]。C反应蛋白与血液透析患者血管钙化相关，是血液透析患者血管钙化发生发展中独立危险因素 [<xref ref-type="bibr" rid="hanspub.40954-ref16">16</xref>]。</p><p>尿酸是嘌呤核苷酸代谢分解的产物。尿酸浓度过高会导致痛风和尿石症。在普通人群中，高尿酸血症与高血压、充血性心力衰竭、代谢综合征、糖尿病、肥胖症、动脉粥样硬化和心血管疾病的风险增加相关 [<xref ref-type="bibr" rid="hanspub.40954-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref20">20</xref>]。近期研究发现高尿酸血症与尿毒症患者的高死亡率直接相关 [<xref ref-type="bibr" rid="hanspub.40954-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.40954-ref22">22</xref>]。此外，国外一项研发现低尿酸血症的患者全因死亡率和心血管病死率高于高尿酸血症的患者 [<xref ref-type="bibr" rid="hanspub.40954-ref23">23</xref>]。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，开始血液透析的年龄增高、炎症及合并糖尿病的MHD患者，其死亡风险增加；而改善营炎症状态，积极纠正贫血，有效控制血钾、血尿酸水平，则利于提高MHD患者的生存率。</p></sec><sec id="s10"><title>基金项目</title><p>青岛市民生科技计划项目(16-6-2-19-nsh)。</p></sec><sec id="s11"><title>文章引用</title><p>刘 媛,单文红,黄俊彦,安 茜,许颖川,解秀荣,季文萱. 维持性血液透析患者的COX生存分析Survival Analysis of Maintenance Hemodialysis Patients[J]. 临床医学进展, 2021, 11(03): 1074-1082. https://doi.org/10.12677/ACM.2021.113154</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40954-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Saran, R., Robinson, B., Abbott, K.C., et al. (2020) US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States. The American Journal of Kidney Diseases, 75, A6-A7.  
&lt;br&gt;https://doi.org/10.1053/j.ajkd.2019.09.002</mixed-citation></ref><ref id="hanspub.40954-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Ebrahimi, V., Khademian, M.H., Masoumi, S.J., et al. (2019) Factors Influencing Survival Time of Hemodialysis Patients; Time to Event Analysis Using Parametric Models: A Cohort Study. BMC Nephrology, 20, 215.  
&lt;br&gt;https://doi.org/10.1186/s12882-019-1382-2</mixed-citation></ref><ref id="hanspub.40954-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Floege, J., Barbour, S.J., Cattran, D.C., et al. (2019) Management and Treatment of Glomerular Diseases (Part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 95, 268-280. &lt;br&gt;https://doi.org/10.1016/j.kint.2018.10.018</mixed-citation></ref><ref id="hanspub.40954-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">闵永龙, 费世枝, 何达, 等. 武汉市血液透析死亡患者流行病学分析[J]. 中国血液净化, 2020, 19(8): 562-565.</mixed-citation></ref><ref id="hanspub.40954-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">张楠楠, 武晴文, 李静, 等. 2013-2015年山西省维持性血液透析患者的流行病学调查[J]. 中华肾脏病杂志, 2018, 34(4): 267-268.</mixed-citation></ref><ref id="hanspub.40954-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">武晴文, 李昊桐, 赵朵, 等. 山西省维持性血液透析患者预后调查(2013年-2016年) [J]. 肾脏病与透析肾移植杂志, 2019, 28(2): 119-123.</mixed-citation></ref><ref id="hanspub.40954-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Zou, Y., Hong, D., He, Q., et al. (2019) Epidemiology Investigation and Analysis of Patients with Hemodialysis in Sichuan Province of China. Renal Failure, 41, 644-649. &lt;br&gt;https://doi.org/10.1080/0886022X.2019.1612429</mixed-citation></ref><ref id="hanspub.40954-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">张艾佳, 张睿, 张睿. 单中心维持性血液透析患者的流行病学特征[J]. 中国老年学杂志, 2019, 39(18): 4514-4516.</mixed-citation></ref><ref id="hanspub.40954-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, Y., Shi, H., Wang, W.M., et al. (2016) Prevalence, Awareness, and Treatment of Anemia in Chinese Patients with Nondialysis Chronic Kidney Disease: First Multicenter, Cross-Sectional Study. Medicine (Baltimore), 95, e3872.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000003872</mixed-citation></ref><ref id="hanspub.40954-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Nangaku, M. (2017) Pathogenesis and Treatment of Anemia in Chronic Kidney Disease. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 58, 1860-1863.</mixed-citation></ref><ref id="hanspub.40954-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Fishbane, S. and Spinowitz, B. (2018) Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. The American Journal of Kidney Diseases, 71, 423-435. &lt;br&gt;https://doi.org/10.1053/j.ajkd.2017.09.026</mixed-citation></ref><ref id="hanspub.40954-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Brunelli, S.M., Du Mond, C., Oestreicher, N., et al. (2017) Serum Potassium and Short-Term Clinical Outcomes among Hemodialysis Patients: Impact of the Long Interdialytic Interval. The American Journal of Kidney Diseases, 70, 21-29. &lt;br&gt;https://doi.org/10.1053/j.ajkd.2016.10.024</mixed-citation></ref><ref id="hanspub.40954-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Karaboyas, A., Zee, J., Brunelli, S.M., et al. (2017) Dialysate Potassium, Serum Potassium, Mortality, and Arrhythmia Events in Hemodialysis: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). The American Journal of Kidney Diseases, 69, 266-77. &lt;br&gt;https://doi.org/10.1053/j.ajkd.2016.09.015</mixed-citation></ref><ref id="hanspub.40954-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Li, G., Ma, H., Yin, Y., et al. (2018) CRP, IL-2 and TNF-α Level in Patients with Uremia Receiving Hemodialysis. Molecular Medicine Reports, 17, 3350-3355. &lt;br&gt;https://doi.org/10.3892/mmr.2017.8197</mixed-citation></ref><ref id="hanspub.40954-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Forghani, M.S., Jadidoleslami, M.S., Naleini, S.N., et al. (2019) Measurement of the Serum Levels of Serum Troponins I and T, Albumin and C-Reactive Protein in Chronic Hemodialysis Patients and Their Relationship with Left Ventricular Hypertrophy and Heart Failure. Diabetology &amp; Metabolic Syndrome, 13, 522-525.  
&lt;br&gt;https://doi.org/10.1016/j.dsx.2018.11.029</mixed-citation></ref><ref id="hanspub.40954-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">莫颖, 任荣, 张艳. 血清胎球蛋白A、C反应蛋白及骨保护素水平与血液透析患者血管钙化相关性研究[J]. 临床肾脏病杂志, 2019, 19(11): 853-856.</mixed-citation></ref><ref id="hanspub.40954-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Stewart, D.J., Langlois, V. and Noone, D. (2019) Hyperuricemia and Hypertension: Links and Risks. Integrated Blood Pressure Control, 12, 43-62. &lt;br&gt;https://doi.org/10.2147/IBPC.S184685</mixed-citation></ref><ref id="hanspub.40954-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Joho, S., Ushijima, R., Nakagaito, M., et al. (2019) Relation between Prognostic Impact of Hyperuricemia and Sympathetic Overactivation in Patients with Heart Failure. Journal of Cardiology, 73, 233-239.  
&lt;br&gt;https://doi.org/10.1016/j.jjcc.2018.08.008</mixed-citation></ref><ref id="hanspub.40954-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">King, C., Lanaspa, M.A., Jensen, T., et al. (2018) Uric Acid as a Cause of the Metabolic Syndrome. Contributions to Nephrology, 192, 88-102. &lt;br&gt;https://doi.org/10.1159/000484283</mixed-citation></ref><ref id="hanspub.40954-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Palazzuoli, A., Hashemi, H., Jameson, L.C., et al. (2017) Hyperuricemia and Cardiovascular Disease. Reviews in Cardiovascular Medicine, 18, 134-145.</mixed-citation></ref><ref id="hanspub.40954-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Petreski, T., Bevc, S., Ekart, R., et al. (2017) Hyperuricemia and Long-Term Survival in Patients with Chronic Kidney Disease Undergoing Hemodialysis. Clinical Nephrology, 88, 69-72. &lt;br&gt;https://doi.org/10.5414/CNP88FX17</mixed-citation></ref><ref id="hanspub.40954-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Petreski, T., Ekart, R., Hojs, R., et al. (2019) Asymptomatic Hyperuricemia and Cardiovascular Mortality in Patients with Chronic Kidney Disease Who Progress to Hemodialysis. International Urology and Nephrology, 51, 1013-1018.  
&lt;br&gt;https://doi.org/10.1007/s11255-019-02154-w</mixed-citation></ref><ref id="hanspub.40954-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sugano, N., Maruyama, Y., Kidoguchi, S., et al. (2019) Effect of Hyperuricemia and Treatment for Hyperuricemia in Japanese Hemodialysis Patients: A Cohort Study. PLoS ONE, 14, e0217859.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0217859</mixed-citation></ref></ref-list></back></article>